Ozçelik H - Search Results

1

P53 protein accumulation in non-invasive lesions surrounding p53 mutation positive invasive breast cancers.

Done SJ, Arneson CR, Ozçelik H, Redston M, Andrulis IL. Done SJ, et al. Among authors: ozcelik h. Breast Cancer Res Treat. 2001 Jan;65(2):111-8. doi: 10.1023/a:1006425809069. Breast Cancer Res Treat. 2001. PMID: 11261826

2

HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry.

Quenneville LA, Phillips KA, Ozcelik H, Parkes RK, Knight JA, Goodwin PJ, Andrulis IL, O'Malley FP. Quenneville LA, et al. Among authors: ozcelik h. Cancer. 2002 Nov 15;95(10):2068-75. doi: 10.1002/cncr.10949. Cancer. 2002. PMID: 12412159 Free article.

3

Type of TP53 mutation and ERBB2 amplification affects survival in node-negative breast cancer.

Ozcelik H, Pinnaduwage D, Bull SB, Andrulis IL. Ozcelik H, et al. Breast Cancer Res Treat. 2007 Nov;105(3):255-65. doi: 10.1007/s10549-006-9452-0. Epub 2007 Jan 13. Breast Cancer Res Treat. 2007. PMID: 17221157

4

p53 mutations in mammary ductal carcinoma in situ but not in epithelial hyperplasias.

Done SJ, Arneson NC, Ozçelik H, Redston M, Andrulis IL. Done SJ, et al. Among authors: ozcelik h. Cancer Res. 1998 Feb 15;58(4):785-9. Cancer Res. 1998. PMID: 9485035

5

Preferential allelic expression can lead to reduced expression of BRCA1 in sporadic breast cancers.

Ozçelik H, To MD, Couture J, Bull SB, Andrulis IL. Ozçelik H, et al. Int J Cancer. 1998 Jul 3;77(1):1-6. doi: 10.1002/(sici)1097-0215(19980703)77:1<1::aid-ijc1>3.0.co;2-y. Int J Cancer. 1998. PMID: 9639385

6

Low levels of expression of an inhibitor of cyclin-dependent kinases (CIP1/WAF1) in primary breast carcinomas with p53 mutations.

Ozçelik H, Mousses S, Andrulis IL. Ozçelik H, et al. Clin Cancer Res. 1995 Aug;1(8):907-12. Clin Cancer Res. 1995. PMID: 9816061

7

Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations.

Phillips KA, Nichol K, Ozcelik H, Knight J, Done SJ, Goodwin PJ, Andrulis IL. Phillips KA, et al. Among authors: ozcelik h. J Natl Cancer Inst. 1999 Mar 3;91(5):469-73. doi: 10.1093/jnci/91.5.469. J Natl Cancer Inst. 1999. PMID: 10070948

8

The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer.

Bull SB, Ozcelik H, Pinnaduwage D, Blackstein ME, Sutherland DA, Pritchard KI, Tzontcheva AT, Sidlofsky S, Hanna WM, Qizilbash AH, Tweeddale ME, Fine S, McCready DR, Andrulis IL. Bull SB, et al. Among authors: ozcelik h. J Clin Oncol. 2004 Jan 1;22(1):86-96. doi: 10.1200/JCO.2004.09.128. J Clin Oncol. 2004. PMID: 14701769

9

SNP-SNP interactions in breast cancer susceptibility.

Onay VU, Briollais L, Knight JA, Shi E, Wang Y, Wells S, Li H, Rajendram I, Andrulis IL, Ozcelik H. Onay VU, et al. Among authors: ozcelik h. BMC Cancer. 2006 May 3;6:114. doi: 10.1186/1471-2407-6-114. BMC Cancer. 2006. PMID: 16672066 Free PMC article.

10

Polymorphisms cMyc-N11S and p27-V109G and breast cancer risk and prognosis.

Figueiredo JC, Knight JA, Cho S, Savas S, Onay UV, Briollais L, Goodwin PJ, McLaughlin JR, Andrulis IL, Ozcelik H. Figueiredo JC, et al. Among authors: ozcelik h. BMC Cancer. 2007 Jun 14;7:99. doi: 10.1186/1471-2407-7-99. BMC Cancer. 2007. PMID: 17567920 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

192 results

Search Page

Filters